Myogenic tumors in nevoid Basal cell carcinoma syndrome

J Pediatr Hematol Oncol. 2015 Mar;37(2):147-9. doi: 10.1097/MPH.0000000000000115.

Abstract

In mice, activated Hedgehog (Hh) signaling induces tumors with myogenic differentiation. In humans, hyperactive Hh signaling due to germline PATCHED1 (PTCH1) mutations has been linked to nevoid basal cell carcinoma syndrome (NBCCS). We report an embryonal rhabdomyosarcoma in a 16-month-old girl with NBCCS and review the literature on myogenic neoplasms in NBCCS, including 8 fetal rhabdomyomas and 3 rhabdomyosarcomas. Of note, 3 population studies, including 255 individuals with NBCCS aged 4 months to 87 years, did not identify any myogenic tumors. Thus, myogenic tumors in NBCCS are rare and include both rhabdomyosarcomas and fetal rhabdomyomas.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Basal Cell Nevus Syndrome / complications*
  • Basal Cell Nevus Syndrome / genetics
  • Basal Cell Nevus Syndrome / pathology
  • Female
  • Humans
  • Infant
  • Mutation / genetics*
  • Patched Receptors
  • Patched-1 Receptor
  • Prognosis
  • Receptors, Cell Surface / genetics*
  • Review Literature as Topic
  • Rhabdomyosarcoma / diagnosis*
  • Rhabdomyosarcoma / etiology

Substances

  • PTCH1 protein, human
  • Patched Receptors
  • Patched-1 Receptor
  • Ptch1 protein, mouse
  • Receptors, Cell Surface